Sino Shenzhou helps the cell blue ocean market and boosts new breakthroughs in the cell biological industry

On the morning of September 20th, the "2022 (13th) Cell Therapy Conference" co-sponsored by Biovalley, Shanghai Oriental Hospital, Tongji Hospital Affiliated to Tongji University, and Chinese Health Science and Technology Promotion Association was officially opened
in Hongqiao, Shanghai.

With the themes of "New Technology Helps Discovery of Targeted Drugs", "Original Research and Innovation Motivation, Seeking Technological Breakthroughs", "Clinical Development and Transformation of Anti-tumor Drugs Oriented by Clinical Value", "Combined Cell Therapy Track", "Whole-process Management and Field Innovation of General Cell Therapy and Cell Therapy Products", "Developing Commercial Application Models for Cell Drug Products", etc.

Mr.

The speech elaborated on the three stages of China's stem cell industry development; Development ideas from personalized therapy to general-purpose cell products; Different access mechanisms
of cellular products are discussed.

Currently
.

According to Mr.

Sino Shenzhou has a complete GMP laboratory, cell bank and carrier library, while the scientific research team led by academicians has been engaged in cell science research for a long time, has made a number of breakthroughs and innovations, has independently developed a number of technologies, obtained dozens of inventions, new application design patents and software production rights, with drug research capabilities, process development capabilities and production capabilities, through a full range of solutions, from the drug research and development front end to penetrate, provide customized services, help enterprises improve R&D efficiency and control risks, The result is the commercialization of
cellular products.

In addition, Sino Shenzhou has rich experience in IND declaration, and can provide one-stop new drug clinical trial application (IND) and new drug listing application (NDA) and other regulatory related services, further helping pharmaceutical companies accelerate the progress of research and development
.

In the future, Sino will continue to improve and optimize the company's management system, improve the ability to develop markets at home and abroad, and provide excellent CDMO services for global customers with open innovation and reliable quality platform system, so that good drugs can benefit the public earlier, and the stem cell health industry will join you!